focus -WSS

focus

author：leisure time 2025-10-02 00:17:58 - browse：34573

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Lawsuit challenges CMS nursing home minimum staffing rule

WSS

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Asahi Kasei to buy Calliditas, picking up kidney disease drug

J&J reports mixed data on next

Achieving telehealth equity for people with hearing loss

The pain doctors face in trying to build their families

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

explore

Tori Bowie and the unacceptable rates of Black maternal death

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Peter Hotez and the public health issue of online harassment

Beware the threat of staffing cuts at the CDC

Medicare details structure of new drug price negotiation program

Cancer drug shortages' outsize impact on ovarian cancer patients

State Dept. review finds Biden bears some blame for Afghanistan failures

Liz Cheney makes 1st public comment since Trump's election interference indictments

Hepatitis C has a cure — but many Americans still lack access to it

Unmasking the 'centricity' illusion in clinical trials

knowledge

Patient advocates sound warning on FDA proposal on salt intake

Congress must give Medicare recipients genetic counseling access

Some medical students still think black patients feel less pain

Hilary may become 1st tropical storm to make landfall in California in 84 years

Protect nursing home residents from future pandemics

Guardant Health colon cancer test endorsed by FDA advisory panel

hotspot

focus

focus

entertainment